| 摘要 |
The means is produced by simplified technology. It potentiates the effect of the intralesion application of cyclophosphamide in solid malignant tumours at manyfold decrease of the effective dose of cyclophosphamide both in single and in general whole-course dose. The means contains polyoxyethylene (20) sobritan trioleate from 20 to 40% solution in physiological solution from 100.0 to 400 g/l, 0.5-0.8% CaCl2.H2O solution, "Decaris" (Levamysol) 2.5-5 mg/l in physiological solution and indomethacine 2.5-5 mg/l in physiological solution.
|
